McQuade Center for Strategic Research and Development Enters Collaboration with Aché to Develop Potential Treatment for General Anxiety Disorder and Post-Traumatic Stress Disorder
Retrieved on:
Tuesday, August 24, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Nephrology, Commercialization, LLC, CNS, Twitter, Innovation Unit, Maintenance, Cardiology, Tuberculosis, Research, Drug discovery, Cosmetics, National university, Doctor of Philosophy, Health, OAPI, Post-traumatic stress disorder, Heart, Mental health, Development, GAD, Creativity, LinkedIn, Patient, Plasma protein binding, PTSD, Pharmaceutical industry, Aché Laboratorios Farmaceuticos S.A., McQuade Center for Strategic Research and Development (MSRD), ACHé LABORATORIOS FARMACEUTICOS S.A., MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT (MSRD)
Therefore, medications with new mechanisms of action are needed with the potential to achieve better therapeutic responses.
Key Points:
- Therefore, medications with new mechanisms of action are needed with the potential to achieve better therapeutic responses.
- We are absolutely thrilled with this collaboration with MSRD, a member of Otsuka, said Vnia Alcantara Machado, president, Ach.
- We believe MSRDs expertise in early-stage programs and Otsukas global leadership position in CNS will be crucial in the development of Achs ACH000029 for GAD and PTSD.
- Ach has a dedicated Innovation Unit focused on the research and development of new medicines, generics, and similar drugs.